Fibrous protein biological adhesive with high adhesion and strong water absorption as well as preparation method and application of fibrous protein biological adhesive

By introducing poly(acrylic-succinimide)-polyethyleneimine network into fibrin glue, a biological adhesive with a dual network system was solved, and severe bleeding was achieved Effective closure and promote wound healing provide a simple and safe treatment option.

CN118924937APending Publication Date: 2024-11-12SHANDONG ACADEMY OF PHARMACEUTICAL SCIENCES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410828974.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-06-25
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The adhesive properties and hemostatic effect of the existing fibrin glue are insufficient, and it cannot effectively seal severe bleeding. The use method is complicated and there is a lack of medical bioadhesive agents that have strong adhesive sealing ability and healing promotion activity.

Method used

Develop a bi-network system bioadhesive based on fibrin, using a combination of poly(acrylic-succinimide)-polyethyleneimine network and fibrin network to form uniform texture through specific mass ratios and structural designs. The dual network system improves the adhesive ability and water absorption performance of the adhesive.

Benefits of technology

It has achieved effective closure of severe bleeding, significantly improved hemostasis and healing performance, simple use, suitable for wet wounds, and has good cellular and hemocompatibility, and is suitable for trauma-assisted treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

The invention provides a biological adhesive, and belongs to the technical field of medical polymer biological materials. The biological adhesive comprises a dual-network system which is formed by a poly (acrylic acid-succinimide)-polyethyleneimine network and a fibrin network and is uniform in texture. The biological adhesive provided by the invention has the properties of rapid water absorption, gelling, adhesion and sealing, and shows excellent hemostasis and healing promotion properties. And the adhesive powder provided by the invention is simple in preparation method, excellent in hemostasis and healing promotion performance and good in biocompatibility.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of medical polymer biomaterials, and in particular to a fibrin-based bioadhesive with high adhesion and strong water absorption, and a preparation method and application thereof. Background Art

[0002] Severe bleeding accounts for 33% of the number of deaths from trauma, and is the main cause of death from trauma. Rapid blood loss and short effective intervention time (< 5 min) are the difficulties in rescuing severe bleeding. Therefore, rapid control and saving the lives of a large number of casualties are of great clinical significance. The traditional method of hemostasis is to use tourniquets or hemostatic dressings to physically pressurize and block blood flow, but this method has limited hemostatic effects and may cause tissue necrosis. Therefore, high-performance hemostatic materials have become a research hotspot for efficient control of bleeding.

[0003] As the end product of the coagulation cascade, fibrin exhibits a faster hemostasis speed. In addition to its advantages in rapid hemostasis, fibrin has the activity of inducing tissue regeneration and promoting rapid wound healing. Research and hemostatic products surrounding it continue to emerge. For example, Chinese invention patent CN112843326A provides a fibrin adhesive fast-acting hemostatic composite powder, which has a simple preparation process and can be stored and transported at room temperature. However, the poor mechanical and adhesive properties of fibrin lead to its limited tissue sealing ability. The bursting pressure of pig skin is only 35 mmHg, which is much lower than the normal blood pressure of the human body (120 mmHg), and it is impossible to achieve effective closure of severe bleeding. Therefore, improving the sealing ability of fibrin is an effective strategy to enhance its hemostatic ability.

[0004] Chinese invention patent CN115779137A provides an interpenetrating network fibrin gel, which is based on fibrin glue and enhances the strength of the gel by introducing a second network therein. However, the hemostatic material provided by the invention needs to be prepared and used immediately, and still faces the problem of complicated use methods. And the adhesive properties of fibrin glue have not been significantly improved. Therefore, in view of the problems existing in the current fibrin glue, it is of great application value to develop an adhesive having strong adhesive sealing ability, easy to use and excellent hemostatic and healing activity. Summary of the invention

[0005] In order to overcome the problem that the existing medical bioadhesive cannot have both adhesive sealing performance and hemostatic and healing promoting activity, the present invention provides a fibrin-based medical bioadhesive powder for rapid wound hemostasis and wound healing promotion.

[0006] In one aspect, the present application provides a bioadhesive, the bioadhesive comprising a double network system with uniform texture formed by a poly(acrylic acid-succinimide)-polyethyleneimine network and a fibrin network;

[0007] The mass ratio of the fibrin network to the poly(acrylic acid-succinimide)-polyethyleneimine network is (0.1-10):(90-99.9);

[0008] The poly(acrylic acid-succinimide)-polyethyleneimine network comprises a network system formed by cross-linking poly(acrylic acid-succinimide) and polyethyleneimine.

[0009] In one embodiment, the double network structure of the bioadhesive provided by the present application has a uniform texture and does not exist in a certain group of analyzed or wrapped forms, indicating that fibrin has good fusion with poly (acrylic acid-succinimide) and polyethylene imine. Preferably, the mass ratio of the fibrin network to the poly (acrylic acid-succinimide)-polyethylene imine network is (0.1-10): (90-99.9), more preferably (0.5-8): (99.5-92), more preferably (1-3): (97-99), more preferably (1.5-2.5): (97.5-98.5), more preferably 2:98; or, by mass percentage, fibrin accounts for 0.5%-10% of the total mass of the double network system, preferably 0.5%-5%, for example 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, more preferably 1.5%-2.5%, more preferably 2%.

[0010] In one embodiment, the mass ratio of the poly(acrylic acid-succinimide) to polyethyleneimine is (0.5-5):(0.5-5), preferably (3-1):(1-2), more preferably (2-1):(1-2), for example, it can be 2:1, 1:1, 1:2, and more preferably 1:1.

[0011] In one embodiment, in the double network system provided by the present application, the molar ratio of N-acryloxysuccinimide in poly(acrylic acid-succinimide) is 5%, the mass ratio of poly(acrylic acid-succinimide) to polyethyleneimine is 1:1, and the mass percentage of fibrin in the double network system is 2%.

[0012] In one embodiment, the polyethyleneimine has the following structural formula:

[0013]

[0014] Preferably, the molecular weight of the polyethyleneimine is 10,000-150,000, for example, 10,000, 20,000, 30,000, 40,000, 50,000, 60,000, 70,000, 80,000, 90,000, 100,000, 110,000, 120,000, 130,000, 140,000, or 150,000.

[0015] Preferably, the molecular weight of the polyethyleneimine is 50,000-100,000, more preferably 60,000-80,000.

[0016] In one embodiment, the poly(acrylic acid-succinimide) has a structure as shown in formula (I):

[0017] ...... (I),

[0018] In formula (I), n is 100-4000, and m is 1-800.

[0019] Among them, the poly(acrylic acid-succinimide) with the above-mentioned degree of polymerization has a certain proportion of succinimide groups and a certain molecular weight, so that the adhesive can have significantly improved bonding ability and more suitable physical and chemical properties for application.

[0020] In one embodiment, the fibrin network is obtained by reacting fibrinogen and thrombin at a mass ratio of (0.5-5):(0.5-5), for example, 3:1, 2:1, 1:1, 1:2, 1:3, etc., preferably 2:1-1:2, more preferably 1:1.

[0021] In one embodiment, the fibrinogen may be of various origins, such as human origin, porcine origin and recombinant fibrinogen, preferably porcine origin.

[0022] In one embodiment, the molecular weight of fibrinogen is 300-400 kDa.

[0023] Alternatively, fibrinogen can be purchased from commercial sources. The molecular weight of commercial fibrinogen is about 340 kDa.

[0024] In one embodiment, the binder is in powder form with a particle size of 10 to 1000 μm.

[0025] Preferably, the average particle size of the binder powder is 10 to 500 μm, more preferably 50 to 200 μm.

[0026] On the other hand, the present application also provides a method for preparing the bioadhesive, comprising:

[0027] Step 1, respectively preparing poly (acrylic acid-succinimide) solution, polyethyleneimine solution, fibrinogen solution and thrombin solution;

[0028] Step 2: Mixing the poly(acrylic acid-succinimide) solution and the thrombin solution to obtain a stock solution 1, and mixing the polyethyleneimine solution and the fibrinogen solution to obtain a stock solution 2; mixing the stock solution 1 and the stock solution 2 to form a hydrogel;

[0029] Step 3: freeze-drying the hydrogel to prepare a powdered bioadhesive.

[0030] In one embodiment, the solvent for preparing the above solutions is water or physiological saline, such as ultrapure water or physiological saline with a sodium chloride concentration of 0.9%.

[0031] In one embodiment, in step 1, the prepared mass concentration of the poly(acrylic acid-succinimide) solution is 5% to 50%, for example, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, etc.

[0032] In one embodiment, in step one, the prepared mass concentration of the polyethyleneimine solution is 5% to 50%, for example, it can be 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, etc.

[0033] In one embodiment, in step one, the prepared mass concentration of the fibrinogen solution is 1% to 20%, for example, 1%, 2%, 4%, 6%, 8%, 10%, 12%, 14%, 16%, 18%, 20%, etc.

[0034] In one embodiment, in step one, the prepared mass concentration of the thrombin solution is 1% to 20%, for example, 1%, 2%, 4%, 6%, 8%, 10%, 12%, 14%, 16%, 18%, 20%, etc.

[0035] In one embodiment, in step 2, stock solution 1 and stock solution 2 are stirred and mixed at room temperature for 60 to 240 seconds, then allowed to stand at 4°C for 3 to 10 minutes, and then transferred to a -40°C refrigerator for freezing for 6 to 24 hours.

[0036] Preferably, the mixing time is 30 to 180 s, for example, 50, 75, 100 and 125 s, to obtain a double network hydrogel.

[0037] Preferably, after the double network hydrogel is prepared, the retention time at 4°C is 3 to 10 min, for example, 3, 5, 7 and 9 min, etc. After standing, the double network hydrogel is transferred to a -40°C refrigerator for freezing.

[0038] In one embodiment, the above solutions may be mixed in equal volumes or in proportion, and the mass ratio of the components in the final solution may be the required mass ratio.

[0039] In one embodiment, the freeze-drying conditions in step 3 are: freeze-drying at -40°C for 3 to 5 days. For example, it can be 3, 4, and 5 days.

[0040] In one embodiment, the hydrogel is freeze-dried to prepare a powder of 10-1000 μm.

[0041] In one embodiment, the hydrogel is freeze-dried and then ground into powder.

[0042] In one embodiment, the grinding time is 5 to 25 min, for example, 5 min, 10 min, 15 min, or 25 min.

[0043] In one embodiment, the grinding process of the hydrogel freeze-dried product is carried out in a dry environment, for example, the grinding can be carried out under an infrared sample preparation lamp.

[0044] In one embodiment, the powdered hydrogel freeze-dried product is sealed and stored at -40°C.

[0045] In one embodiment, the poly(acrylic acid-succinimide) is prepared by polymerization of acrylic acid and N-acryloyloxysuccinimide, and the reaction molar ratio is (100-4000): (1-800).

[0046] Specifically, the polymerization reaction is reversible addition-fragmentation chain transfer polymerization (RAFT).

[0047] In one embodiment, the feed ratio of N-acryloxysuccinimide in poly(acrylic acid-succinimide) is 0.01% to 25% of the total molar number of acrylic acid and N-acryloxysuccinimide, for example, it can be 0.01%, 1%, 5%, 10%, 15%, 20% and 25%, etc., preferably 1% to 20%.

[0048] In one embodiment, the solvent for the polymerization reaction is N,N-dimethylacetamide.

[0049] In one embodiment, the N,N-dimethylacetamide solvent is an ultra-dry solvent.

[0050] In one embodiment, an initiator and a chain transfer agent are further added into the reaction.

[0051] In one embodiment, the molar ratio of the acrylic acid, N-acryloxysuccinimide initiator and chain transfer agent is (100-4000):(1-800):1:(0.2-0.4).

[0052] In one embodiment, the initiator is 4-cyano-4-[[(dodecylthio)thionemethyl]thio]pentanoic acid.

[0053] In one embodiment, the chain transfer agent is azobisisobutyronitrile.

[0054] In one embodiment, the volume ratio of the mass of acrylic acid, N-acryloyloxysuccinimide, 4-cyano-4-[[(dodecylthio)thioketonemethyl]thio]pentanoic acid and azobisisobutyronitrile to the N,N-dimethylacetamide solvent is 1:(3-5).

[0055] In one embodiment, the reaction conditions are: reacting at 65° C. to 75° C. for 15 to 30 h in a closed environment without oxygen.

[0056] In one embodiment, deoxygenation is performed by passing a non-reactive gas, such as nitrogen or an inert gas.

[0057] In one embodiment, the reaction is followed by dialysis and freeze-drying.

[0058] In one embodiment, the dialysis time is 2 to 5 days, the water change frequency during the dialysis process is 2 to 6 times / d, and the molecular weight cutoff of the dialysis bag is 500 to 5000 Da.

[0059] In one embodiment, the freeze-drying method comprises: freeze-drying at -40°C for 2 to 5 days.

[0060] On the other hand, the present application provides the use of the medical adhesive, or the medical adhesive prepared by the preparation method, in the preparation of trauma auxiliary treatment products.

[0061] In one embodiment, the trauma adjuvant therapy includes, but is not limited to, areas such as hemostasis and wound protection, tissue sealing, drug delivery, injury protection, injury repair or biological scaffolds.

[0062] In one embodiment, according to the actual application scenario, conventional additive components in the art may be added to the adhesive network system provided in the present application, or other active functional ingredients may be added to make it have other active functions.

[0063] In one embodiment, the bioadhesive has a gelling time of less than 5 s when exposed to water.

[0064] In one embodiment, the water absorption capacity of the bioadhesive is 0.5 to 2.5 times its own mass.

[0065] In one embodiment, the bioadhesive is suitable for use in moist wounds and / or dynamic wounds.

[0066] In one embodiment, the wound is a hemorrhagic wound, including organ bleeding caused by accidental trauma or occurring during surgery.

[0067] Alternatively, the organ may be the liver, spleen, kidney, gastrointestinal tract, heart or skin.

[0068] In one embodiment, the sealing burst pressure of the bioadhesive on biological tissue is greater than or equal to 120 mmHg, preferably greater than or equal to 150 mmHg, and more preferably greater than or equal to 180 mmHg.

[0069] Optionally, the biological tissue includes porcine small intestine tissue.

[0070] In one embodiment, the method of using the bioadhesive is as follows:

[0071] Take an appropriate amount of the medical adhesive powder and directly cover the wound surface. Within a few seconds, the powder absorbs blood or tissue fluid on the wound surface to form a hydrogel sealing layer.

[0072] This application has at least the following technical advantages or effects:

[0073] 1. In the preparation and use method of the medical adhesive powder provided by the present invention, the raw material synthesis, adhesive preparation and powder making processes are simple, the storage and transportation conditions of the obtained adhesive powder are simple, the use method is simple, and the application range is wide.

[0074] 2. The bioadhesive provided in the present application is normally stored in a powder dosage form. On the one hand, compared with other dosage forms, it is not easy to age and deteriorate and has a long storage time; on the other hand, the solid powder dosage form itself has good water absorption capacity, and the adhesive prepared in the present application adopts a double network system with a uniform structure and texture formed by the fusion of a poly(acrylic acid-succinimide)-polyethyleneimine network and a fibrin network, and has a rich porous network structure, which further improves its water absorption advantage, and is particularly suitable for the adhesion of wet wounds, and can assist in absorbing bleeding and exudate from wet wounds. In particular, fibrin can promote coagulation and wound healing, which is significantly beneficial to the treatment and healing of wet wounds.

[0075] 3. The bioadhesive provided by the present application, in which the poly (acrylic acid-succinimide) contains succinimide groups, can form covalent bonds with another component, polyethyleneimine, and amino groups on the surface of biological tissues, which enhances the strength of the gel itself and the adhesion strength to the target surface. Combined with the procoagulant and healing properties of fibrin, it can have both the adhesion and sealing properties of wounds and the procoagulant and healing activities, so that its application range can be expanded to tissue sealing, drug delivery, active substance carriers, and biological scaffolds. In addition, at a specific succinimide group content ratio and molecular weight, the prepared adhesive can have more suitable physical and chemical properties for application, as well as significantly improved adhesion ability.

[0076] 4. The freeze-dried powder prepared by compounding poly(acrylic acid-succinimide) and polyethyleneimine in the present application can have a porous structure of a more stable cross-linked network system, and its network structure and mechanical properties are not affected after freeze-drying and repeated water absorption freeze-drying treatment. In addition, the adhesive powder prepared by poly(acrylic acid-succinimide) and polyethyleneimine at a specific mass ratio will not be too thin or too hardened after absorbing water, and will not lose the adhesive ability, and can show better adhesive performance.

[0077] 5. The adhesive provided in the present application can better fuse with the poly(acrylic acid-succinimide)-polyethyleneimine network at a specific fibrin content, thereby maintaining significantly improved mechanical properties while having excellent pro-coagulant function, especially the sealing burst pressure for biological tissues is as high as 180 mmHg, which can achieve effective sealing of wounds.

[0078] 6. The adhesive provided in this application also has good cell compatibility and blood compatibility, is safer to use, and has good biocompatibility.

[0079] 7. The adhesive provided in the present application has a fast gelling speed when in contact with water, has a good water absorption capacity, does not harden after absorbing water to form a gel, and has strong mechanical properties for bonding, and can be applied to various irregular surfaces, especially dynamic surfaces, and is not prone to peeling. BRIEF DESCRIPTION OF THE DRAWINGS

[0080] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments recorded in the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0081] Figure 1 The preparation route of the fibrin-based adhesive powder of the present application and the schematic diagram of the gelling process when it comes into contact with water;

[0082] Figure 2 H NMR spectra of poly(acrylic acid-succinimide) and polyacrylic acid after dialysis for 1, 2 and 3 days;

[0083] Figure 3 The scanning electron microscopy results of the poly(acrylic acid-succinimide)-polyethyleneimine single network, the scale bar of the left image is 100μm, and the scale bar of the right image is 400μm;

[0084] Figure 4 The scanning electron microscopy results of the fibrin and poly (acrylic acid-succinimide)-polyethyleneimine double network system are shown in the figure. The scale bar of the left figure is 100 μm, and the scale bar of the right figure is 400 μm.

[0085] Figure 5 The lap-shear strength results of the adhesive of this application with different fibrin contents and different substrates are shown in the figure;

[0086] Figure 6 The graph is the shear strength result of adhesives with different mass ratios of poly (acrylic acid-succinimide) and polyethyleneimine and different fibrin contents;

[0087] Figure 7 is a diagram showing the hemolysis test results of the prepared bioadhesive;

[0088] Figure 8 The figure is the result of the procoagulant experiment of the prepared bioadhesive;

[0089] Fig. 9 A schematic diagram of a test device for the sealing ability of the prepared bioadhesive on biological tissues;

[0090] Fig.10 The figure is a test result of the sealing ability of the prepared bioadhesive to biological tissues;

[0091] Fig.11 is a diagram showing the hemostasis test results of the prepared bioadhesive;

[0092] Fig.12 This is a graph showing the experimental results of the prepared bioadhesive promoting wound healing. DETAILED DESCRIPTION

[0093] In order to more clearly explain the overall concept of the application, the following is described in detail by way of embodiment. In the following description, a large amount of specific details are provided so as to provide a more thorough understanding of the application. However, it is obvious to those skilled in the art that the application can be implemented without one or more of these details. In other examples, in order to avoid confusion with the application, some technical features well known in the art are not described.

[0094] The technical scheme of the present invention is further described in detail below in conjunction with several preferred embodiments and accompanying drawings. Obviously, the described embodiments are only a part of embodiments of the present invention, rather than all embodiments. Based on the embodiments in the present invention, all other embodiments obtained by those of ordinary skill in the art without making creative work belong to the scope of protection of the present invention. It should be noted that the experimental methods adopted in the following preparation examples and embodiments, if not otherwise specified, are conventional methods, and the reagents used in the preparation examples and embodiments, if not otherwise specified, are reagents supplied by conventional reagent manufacturers.

[0095] The experimental reagents and experimental instrument information involved in the following examples are shown in Table 1:

[0096] Table 1 Reagent and instrument information

[0097] Example 1

[0098] This preparation example provides a fibrin-based adhesive powder, and the preparation method thereof comprises the following steps:

[0099] 1. Preparation of poly(acrylic acid-succinimide), comprising the following steps:

[0100] (1) Add 8.208 g acrylic acid (0.114 mol), 1.014 g N-acryloyloxysuccinimide (0.006 mol), 0.024 g 4-cyano-4-[[(dodecylthio)thiomethyl]thio]pentanoic acid and 0.0029 g azobisisobutyronitrile to 37.00 mL ultra-dry N,N-dimethylacetamide;

[0101] (2) adding magnetrons to the solution of step (1) and deoxygenating with Ar gas for 45 min;

[0102] (3) The reaction solution in step (2) was sealed and placed in an oil bath at 70°C for 24 h;

[0103] (4) After the reaction is completed, the reaction solution is poured into a dialysis bag (molecular weight cutoff 1000 Da) and dialyzed for 3 days, and freeze-dried for 3 days to obtain poly(acrylic acid-succinimide) with a molar ratio of N-acryloylsuccinimide to feed of 5%.

[0104] 2. The poly(acrylic acid-succinimide) prepared in this example is mixed with polyethyleneimine, fibrinogen and thrombin to prepare a glue, and then freeze-dried to obtain a fibrin-based adhesive powder. The specific steps are as follows:

[0105] (1) Preparation of adhesives: Dissolve 0.99 g poly(acrylic acid-succinimide) (N-acryloyl succinimide feed ratio 5%) in saline to prepare a 20% poly(acrylic acid-succinimide) solution; dissolve 0.99 g polyethyleneimine (molecular weight 10,000) in saline to prepare a 20% polyethyleneimine solution; dissolve 0.02 g thrombin in saline to prepare a 2% thrombin solution; dissolve 0.02 g fibrinogen in saline to prepare a 2% fibrinogen solution. Thoroughly mix the poly(acrylic acid-succinimide) solution and the thrombin solution to prepare stock solution 1; thoroughly mix the polyethyleneimine solution and the fibrinogen solution to prepare stock solution 2. Equal volumes of stock solution 1 and stock solution 2 were mixed and stirred for 60 s to obtain a double network hydrogel with uniform structure and texture formed by a fibrin network and a poly (acrylic acid-succinimide)-polyethyleneimine network.

[0106] (2) Powder preparation: After stirring the double network hydrogel in step (1), let it stand at room temperature for 3 min and then transfer it to a -40 °C refrigerator for 12 h, and then freeze-dry it for 3 days; the freeze-dried product of the double network hydrogel is ground for 5 min under infrared sample preparation to obtain a fibrin-based adhesive powder, which is recorded as PNPF-1.

[0107] Example 2

[0108] This preparation example provides a fibrin-based adhesive powder, and the preparation method thereof comprises the following steps:

[0109] 1. The preparation method of poly(acrylic acid-succinimide) comprises the following steps:

[0110] (1) Add 8.208 g acrylic acid (0.114 mol), 1.014 g N-acryloyloxysuccinimide (0.006 mol), 0.024 g 4-cyano-4-[[(dodecylthio)thiomethyl]thio]pentanoic acid and 0.0029 g azobisisobutyronitrile to 37.00 mL ultra-dry N,N-dimethylacetamide;

[0111] (2) adding magnetrons to the solution of step (1) and deoxygenating with Ar gas for 45 min;

[0112] (3) The reaction solution in step (2) was sealed and placed in an oil bath at 70°C for 24 h;

[0113] (4) After the reaction is completed, the reaction solution is poured into a dialysis bag (molecular weight cutoff 1000 Da) and dialyzed for 3 days, and freeze-dried for 3 days to obtain poly(acrylic acid-succinimide) with a molar ratio of N-acryloylsuccinimide to feed of 5%.

[0114] 2. The poly(acrylic acid-succinimide) prepared in this example is mixed with polyethyleneimine, fibrinogen and thrombin to prepare a glue, and then freeze-dried to obtain a fibrin-based adhesive powder. The specific steps are as follows:

[0115] (1) Preparation of adhesives: Dissolve 0.98 g of poly(acrylic acid-succinimide) (N-acryloyl succinimide feed ratio 5%) in saline to prepare a 20% poly(acrylic acid-succinimide) solution; dissolve 0.98 g of polyethyleneimine (molecular weight 10,000) in saline to prepare a 20% polyethyleneimine solution; dissolve 0.04 g of thrombin in saline to prepare a 4% thrombin solution; dissolve 0.04 g of fibrinogen in saline to prepare a 4% fibrinogen solution. Thoroughly mix the poly(acrylic acid-succinimide) solution and the thrombin solution to prepare stock solution 1; thoroughly mix the polyethyleneimine solution and the fibrinogen solution to prepare stock solution 2. Equal volumes of stock solution 1 and stock solution 2 were mixed and stirred for 120 s to obtain a double network hydrogel with uniform structure and texture formed by a fibrin network and a poly (acrylic acid-succinimide)-polyethyleneimine network.

[0116] (2) Powder preparation: After stirring the double network hydrogel in step (1), let it stand at room temperature for 5 min and then transfer it to a -40 °C refrigerator for 16 h, and then freeze-dry it for 4 days; the freeze-dried product of the double network hydrogel is ground for 10 min under infrared sample preparation to obtain a fibrin-based adhesive powder, which is recorded as PNPF-2.

[0117] Example 3

[0118] This preparation example provides a fibrin-based adhesive powder, and the preparation method thereof comprises the following steps:

[0119] 1. The preparation method of poly(acrylic acid-succinimide) comprises the following steps:

[0120] (1) Add 8.208 g acrylic acid (0.114 mol), 1.014 g N-acryloyloxysuccinimide (0.006 mol), 0.024 g 4-cyano-4-[[(dodecylthio)thiomethyl]thio]pentanoic acid and 0.0029 g azobisisobutyronitrile to 37.00 mL ultra-dry N,N-dimethylacetamide;

[0121] (2) adding magnetrons to the solution of step (1) and deoxygenating with Ar gas for 45 min;

[0122] (3) The reaction solution in step (2) was sealed and placed in an oil bath at 70°C for 24 h;

[0123] (4) After the reaction is completed, the reaction solution is poured into a dialysis bag (molecular weight cutoff 1000 Da) and dialyzed for 3 days, and freeze-dried for 3 days to obtain poly(acrylic acid-succinimide) with a molar ratio of N-acryloylsuccinimide to feed of 5%.

[0124] 2. The poly(acrylic acid-succinimide) prepared in this example is mixed with polyethyleneimine, fibrinogen and thrombin to prepare a glue, and then freeze-dried to obtain a fibrin-based adhesive powder. The specific steps are as follows:

[0125] (1) Preparation of adhesives: Dissolve 0.97 g of poly(acrylic acid-succinimide) (N-acryloyl succinimide feed ratio 5%) in saline to prepare a 20% poly(acrylic acid-succinimide) solution; dissolve 0.97 g of polyethyleneimine (molecular weight 10,000) in saline to prepare a 20% polyethyleneimine solution; dissolve 0.06 g of thrombin in saline to prepare a 6% thrombin solution; dissolve 0.06 g of fibrinogen in saline to prepare a 6% fibrinogen solution. Thoroughly mix the poly(acrylic acid-succinimide) solution and the thrombin solution to prepare stock solution 1; thoroughly mix the polyethyleneimine solution and the fibrinogen solution to prepare stock solution 2. The stock solution 1 and the stock solution 2 were mixed in equal volumes and stirred for 180 s to obtain a double network hydrogel with uniform structure and texture formed by a fibrin network and a poly (acrylic acid-succinimide)-polyethyleneimine network.

[0126] (2) Powder preparation: After stirring the double network hydrogel in step (1), let it stand at room temperature for 7 min and then transfer it to a -40 °C refrigerator for 20 h, and then freeze-dry it for 5 days; the freeze-dried product of the double network hydrogel is ground for 15 min under infrared sample preparation to obtain a fibrin-based adhesive powder, which is recorded as PNPF-3.

[0127] Example 4

[0128] This preparation example provides a fibrin-based adhesive powder, and the preparation method thereof comprises the following steps:

[0129] 1. The preparation method of poly(acrylic acid-succinimide) comprises the following steps:

[0130] (1) Add 8.208 g acrylic acid (0.114 mol), 1.014 g N-acryloyloxysuccinimide (0.006 mol), 0.024 g 4-cyano-4-[[(dodecylthio)thiomethyl]thio]pentanoic acid and 0.0029 g azobisisobutyronitrile to 37.00 mL ultra-dry N,N-dimethylacetamide;

[0131] (2) adding magnetrons to the solution of step (1) and deoxygenating with Ar gas for 45 min;

[0132] (3) The reaction solution in step (2) was sealed and placed in an oil bath at 70°C for 24 h;

[0133] (4) After the reaction is completed, the reaction solution is poured into a dialysis bag (molecular weight cutoff 1000 Da) and dialyzed for 3 days, and freeze-dried for 3 days to obtain poly(acrylic acid-succinimide) with a molar ratio of N-acryloylsuccinimide to feed of 5%.

[0134] 2. The poly(acrylic acid-succinimide) prepared in this example is mixed with polyethyleneimine, fibrinogen and thrombin to prepare a glue, and then freeze-dried to obtain a fibrin-based adhesive powder. The specific steps are as follows:

[0135] (1) Preparation of adhesives: Dissolve 0.92 g of poly(acrylic acid-succinimide) (N-acryloyl succinimide feed ratio 5%) in saline to prepare a 20% poly(acrylic acid-succinimide) solution; dissolve 0.92 g of polyethyleneimine (molecular weight 10,000) in saline to prepare a 20% polyethyleneimine solution; dissolve 0.16 g of thrombin in saline to prepare a 16% thrombin solution; dissolve 0.16 g of fibrinogen in saline to prepare a 16% fibrinogen solution. Thoroughly mix the poly(acrylic acid-succinimide) solution and the thrombin solution to prepare stock solution 1; thoroughly mix the polyethyleneimine solution and the fibrinogen solution to prepare stock solution 2. Equal volumes of stock solution 1 and stock solution 2 were mixed and stirred for 240 s to obtain a double network hydrogel with uniform structure and texture formed by a fibrin network and a poly (acrylic acid-succinimide)-polyethyleneimine network.

[0136] (2) Powder preparation: After the double network hydrogel is stirred in step (1), it is allowed to stand at room temperature for 10 min and then transferred to a -40 °C refrigerator for 24 h, and then freeze-dried for 5 d. The freeze-dried product of the double network hydrogel is ground under infrared sample preparation for 25 min to obtain a fibrin-based adhesive powder, which is designated as PNPF-8.

[0137] Example 5

[0138] This preparation example provides a fibrin-based adhesive powder, and the preparation method thereof comprises the following steps:

[0139] 1. The preparation method of poly(acrylic acid-succinimide) comprises the following steps:

[0140] (1) Add 8.208 g acrylic acid (0.114 mol), 1.014 g N-acryloyloxysuccinimide (0.006 mol), 0.024 g 4-cyano-4-[[(dodecylthio)thiomethyl]thio]pentanoic acid and 0.0029 g azobisisobutyronitrile to 37.00 mL ultra-dry N,N-dimethylacetamide;

[0141] (2) adding magnetrons to the solution of step (1) and deoxygenating with Ar gas for 45 min;

[0142] (3) The reaction solution in step (2) was sealed and placed in an oil bath at 70°C for 24 h;

[0143] (4) After the reaction is completed, the reaction solution is poured into a dialysis bag (molecular weight cutoff 1000 Da) and dialyzed for 3 days, and freeze-dried for 3 days to obtain poly(acrylic acid-succinimide) with a molar ratio of N-acryloylsuccinimide to feed of 5%.

[0144] 2. The poly(acrylic acid-succinimide) prepared in this example is mixed with polyethyleneimine, fibrinogen and thrombin to prepare a glue, and then freeze-dried to obtain a fibrin-based adhesive powder. The specific steps are as follows:

[0145] (1) Preparation of adhesives: Dissolve 0.98 g of poly(acrylic acid-succinimide) (N-acryloyl succinimide feed ratio 5%) in saline to prepare a 20% poly(acrylic acid-succinimide) solution; dissolve 0.98 g of polyethyleneimine (molecular weight 10,000) in saline to prepare a 20% polyethyleneimine solution; dissolve 0.08 g of thrombin in saline to prepare an 8% thrombin solution; dissolve 0.04 g of fibrinogen in saline to prepare a 4% fibrinogen solution. Thoroughly mix the poly(acrylic acid-succinimide) solution and the thrombin solution to prepare stock solution 1; thoroughly mix the polyethyleneimine solution and the fibrinogen solution to prepare stock solution 2. Equal volumes of stock solution 1 and stock solution 2 were mixed and stirred for 240 s to obtain a double network hydrogel with uniform structure and texture formed by a fibrin network and a poly (acrylic acid-succinimide)-polyethyleneimine network.

[0146] (2) Powder preparation: After stirring the double network hydrogel in step (1), let it stand at room temperature for 10 minutes, transfer it to a -40°C refrigerator and freeze it for 24 hours, and then freeze-dry it for 5 days; the freeze-dried product of the double network hydrogel is ground for 25 minutes under infrared sample preparation, etc., to obtain a fibrin-based adhesive powder.

[0147] Example 6

[0148] This preparation example provides a fibrin-based adhesive powder, and the preparation method thereof comprises the following steps:

[0149] 1. The preparation method of poly(acrylic acid-succinimide) comprises the following steps:

[0150] (1) Add 8.208 g acrylic acid (0.114 mol), 1.014 g N-acryloyloxysuccinimide (0.006 mol), 0.024 g 4-cyano-4-[[(dodecylthio)thiomethyl]thio]pentanoic acid and 0.0029 g azobisisobutyronitrile to 37.00 mL ultra-dry N,N-dimethylacetamide;

[0151] (2) adding magnetrons to the solution of step (1) and deoxygenating with Ar gas for 45 min;

[0152] (3) The reaction solution in step (2) was sealed and placed in an oil bath at 70°C for 24 h;

[0153] (4) After the reaction is completed, the reaction solution is poured into a dialysis bag (molecular weight cutoff 1000 Da) and dialyzed for 3 days, and freeze-dried for 3 days to obtain poly(acrylic acid-succinimide) with a molar ratio of N-acryloylsuccinimide to feed of 5%.

[0154] 2. The poly(acrylic acid-succinimide) prepared in this example is mixed with polyethyleneimine, fibrinogen and thrombin to prepare a glue, and then freeze-dried to obtain a fibrin-based adhesive powder. The specific steps are as follows:

[0155] (1) Preparation of adhesives: Dissolve 0.96 g of poly(acrylic acid-succinimide) (N-acryloyl succinimide feed ratio 5%) in saline to prepare a 20% poly(acrylic acid-succinimide) solution; dissolve 0.96 g of polyethyleneimine (molecular weight 10,000) in saline to prepare a 20% polyethyleneimine solution; dissolve 0.04 g of thrombin in saline to prepare a 4% thrombin solution; dissolve 0.08 g of fibrinogen in saline to prepare an 8% fibrinogen solution. Thoroughly mix the poly(acrylic acid-succinimide) solution and the thrombin solution to prepare stock solution 1; thoroughly mix the polyethyleneimine solution and the fibrinogen solution to prepare stock solution 2. Equal volumes of stock solution 1 and stock solution 2 were mixed and stirred for 240 s to obtain a double network hydrogel with uniform structure and texture formed by a fibrin network and a poly (acrylic acid-succinimide)-polyethyleneimine network.

[0156] (2) Powder preparation: After stirring the double network hydrogel in step (1), let it stand at room temperature for 10 minutes, transfer it to a -40°C refrigerator and freeze it for 24 hours, and then freeze-dry it for 5 days; the freeze-dried product of the double network hydrogel is ground for 25 minutes under infrared sample preparation, etc., to obtain a fibrin-based adhesive powder.

[0157] The reaction process and reaction formula involved in the above embodiments are as follows Figure 1 shown.

[0158] Test Example 1

[0159] This test example evaluates the structural characteristics of the prepared fibrin-based adhesive powder.

[0160] The poly(acrylic acid-succinimide) prepared in the above example with a molar ratio of 5% of N-acryloyl succinimide was characterized by hydrogen nuclear magnetic resonance. The evaluation method was as follows: 15 mg of the poly(acrylic acid-succinimide) solid was weighed, dissolved in 500 μL of heavy water, mixed evenly, and transferred to a nuclear magnetic resonance tube for nuclear magnetic resonance analysis. The results are shown in Figure 2 .

[0161] Depend on Figure 2It can be seen that the characteristic peak of N-acryloyl succinimide appears in the nuclear magnetic resonance hydrogen spectrum, indicating that the synthesis of poly (acrylic acid-succinimide) is successful. In addition, according to the peak area analysis, it can be obtained that the succinimide ester group accounts for 0.5% of the total molar number of the poly (acrylic acid-succinimide) unit. Therefore, its structural formula can be judged as:

[0162] ...... (I),

[0163] Among them, in the structural formula (I) of poly(acrylic acid-succinimide) with a feed molar ratio of N-acryloyl succinimide of 5%, n is 3800 and m is 200. The above embodiment only provides an optional implementation of poly(acrylic acid-succinimide). In the structural formula (I) of the present application, n can be 100-4000 and m can be 1-800.

[0164] Based on this, the embodiments provided in this application prepare poly(acrylic acid-succinimide), and then after mixing it with polyethyleneimine and fibrin, a composite adhesive containing these three components can be prepared.

[0165] At the same time, the present application attempts to replace polyethyleneimine with ε-polylysine or carboxymethyl chitosan. However, the obtained poly(acrylic acid-succinimide) and ε-polylysine do not form a hydrogel or a precipitate after mixing; after the obtained poly(acrylic acid-succinimide) and carboxymethyl chitosan are mixed, a precipitate is precipitated in the solution, but the precipitate is a loose flocculent precipitate and cannot form a hydrogel. Therefore, compared with other conventional preparations that can be used to prepare hydrogels, polyethyleneimine is more suitable for compounding with the obtained poly(acrylic acid-succinimide) to form a hydrogel adhesive with a network system.

[0166] The microstructural characterization process of poly(acrylic acid-succinimide)-polyethyleneimine single network (PNP) and poly(acrylic acid-succinimide)-polyethyleneimine / fibrin double network (PNPF) is as follows:

[0167] Evaluation method:

[0168] The poly(acrylic acid-succinimide) solution and the polyethyleneimine solution in the above-mentioned embodiment with a mass ratio of 1:1 were fully stirred and mixed to obtain a hydrogel, and then the same freeze-drying step was used for powdering to obtain a poly(acrylic acid-succinimide)-polyethyleneimine single network (PNP), which can be recorded as PNPF-0; the prepared sample was pasted on the conductive glue of the scanning electron microscope sample stage, sprayed with gold, and transferred to the scanning electron microscope studio to observe the surface morphology of the sample. The results are shown in Figure 3 ;

[0169] The adhesive powder of poly (acrylic acid-succinimide)-polyethyleneimine / fibrin double network (PNPF) prepared in Example 2 was made into a sample and pasted on the conductive glue of the scanning electron microscope sample stage, sprayed with gold, and transferred to the scanning electron microscope studio to observe the surface morphology of the sample. The results are shown in Figure 4 .

[0170] Performance Characterization: Comparison Figure 3 and Figure 4 The results show that there is no significant difference in the microstructure of freeze-dried PNP and PNPF gels, and the surface layer shows a dense and void-free structure, which is about 50 μm thick. Below the surface, it shows a porous structure with a wide distribution of pore sizes, ranging from tens to hundreds of microns, and most of these pores are not connected. PNP and PNPF powders did not show significant differences, with particle sizes ranging from 10 to 200 μm and irregular particle shapes. This result shows that the addition of the fibrin network has no significant effect on the microstructure of the PNP gel, and the gel structure has a uniform texture, which shows that the two networks are well intertwined and fused with each other, and fibrin and poly (acrylic acid-succinimide)-polyethyleneimine also have good fusion.

[0171] Test Example 2

[0172] This test example evaluates the adhesive performance of the prepared fibrin-based adhesive powder.

[0173] Evaluation method: Prepare poly(acrylic acid-succinimide)-polyethyleneimine single network (PNP) and poly(acrylic acid-succinimide)-polyethyleneimine / fibrin double network (PNPF) adhesive powders respectively. The bonding performance of the prepared adhesive powders was evaluated by lap shear test. The operation is as follows:

[0174] Two pieces of glass, polytetrafluoroethylene (PTFE), polyethylene terephthalate (PET), iron (Fe), polypropylene (PP), and polymethyl methacrylate (PMMA) with a length of 5.5 cm, a width of 2 cm, and a thickness of 0.15 cm were overlapped with a contact area of ​​2 cm in length and 1 cm in width. The contact surfaces were bonded and connected with an adhesive. Water 1 to 1.5 times its mass was added to the adhesive in advance to prepare an adhesive hydrogel. The amount used was based on completely covering the contact area. The unoverlapped part of the adhesive substrate was fixed on the material machine fixture. A 50 N sensor was used to test at a constant tensile speed of 10 mm / min. The shear strength was determined by dividing the maximum load force by the adhesion area.

[0175] The lap shear strength is calculated using the following formula:

[0176] Shear strength = FL / (w×l),

[0177] Where FL is the maximum load during the stretching process, w and l are the width and length of the overlapping surface of the bonding substrate, respectively.

[0178] Performance characterization: Figure 5 As shown in the figure, PNPF exhibits high adhesion strength to different substrate materials, which is higher than the normal blood pressure of the human body (≈ 16 kPa). It is suitable for human hemostasis and auxiliary use of medical devices made of different materials.

[0179] Test Example 3

[0180] This test example optimizes the ratio of poly(acrylic acid-succinimide) and polyethyleneimine after adding fibrin.

[0181] According to the preparation method of the aforementioned Examples 1-6, the volume ratios of poly(acrylic acid-succinimide) and polyethyleneimine were set to 1:2, 1:1 and 2:1, respectively, and adhesives with mass percentages of 1%, 2% and 3% were prepared with fibrin, respectively. A total of 9 samples were prepared, and their adhesive properties were evaluated.

[0182] Evaluation method: The bonding performance of the prepared adhesive powder was evaluated by lap shear test on the 9 samples prepared. The operation is as follows:

[0183] Two sheets of polypropylene (PP) with a specification of 5.5 cm in length, 2 cm in width, and 0.15 cm in thickness were overlapped with a contact area of ​​2 cm in length and 1 cm in width, and the contact surfaces were bonded and connected with an adhesive. Water 1 to 1.5 times its mass was added to the adhesive in advance to prepare an adhesive hydrogel. Other evaluation methods were the same as those in Test Example 2. The results are shown in Figure 2. Figure 6 shown.

[0184] Performance characterization: Figure 6 As shown in the figure, the PNPF hydrogel prepared with a PAA-NHS:PEI mass ratio of 1:1 exhibited the highest adhesion strength, which was significantly higher than that of the ratios of 1:2 and 2:1. In the group with a PAA-NHS:PEI mass ratio of 1:1, the adhesion strength of the PNPF hydrogels with fibrin contents of 1% (12.61±2.01 kPa) and 2% (17.33±1.90 kPa) was significantly greater than that of the PNPF hydrogels with a fibrin content of 3% (8.50±2.37 kPa). However, when the mass ratio of PAA:PEI was 1:2 and 2:1, the effect of fibrin content on adhesion strength was not obvious. Based on the above results, the PAA-NHS:PEI mass ratio of 1:1 was determined to be the preferred ratio.

[0185] Test Example 4

[0186] This test example evaluates the blood compatibility of the prepared dual network adhesive powder.

[0187] Evaluation method: The blood compatibility of PNPF was evaluated by testing its hemolysis rate. Whole blood collected from the heart of Sprague-Dawley rats (SD rats) was mixed with the anticoagulant citrate-dextrose solution (ACD, 20 mM citric acid, 110 mM sodium citrate, 5 mM D-glucose) at a volume ratio of 9:1, and then centrifuged (120×g) for 10 min to collect red blood cells (RBCs), which were then diluted with PBS to a final concentration of 5% (v / v). Next, PNPF powder samples (5 mg or 10 mg) were dispersed in 5% RBSs suspension (1 mL) at 37°C and incubated for 1 h, and then centrifuged at 10000×g for 10 min to precipitate the PNPF samples. The absorbance of the supernatant (at 540 nm) was measured by a microplate reader. RBCs diluted with PBS at a concentration of 5% (v / v) and distilled water were used as positive and negative controls, respectively.

[0188] The hemolysis rate of the sample was calculated by the following equation:

[0189] Hemolysis rate = (ODs - ODp) / (ODn - ODp)×100%,

[0190] Among them, ODs, ODn and ODp are the absorbance of the supernatant of PNPF sample, negative control and positive control respectively. Figure 7 shown.

[0191] Performance characterization: Figure 7 As shown, PNPF did not undergo obvious hemolysis, indicating that the fibrin-based adhesive powder had good blood compatibility.

[0192] Test Example 5

[0193] This test example evaluates the procoagulant activity of the prepared fibrin-based adhesive powder.

[0194] Evaluation method: According to the preparation method described in the previous example, adhesive powders PNPF-0, PNPF-1, PNPF-2 and PNPF-3 were prepared and placed at the bottom of polypropylene tubes respectively. Recalcified ACD whole blood (0.2 M CaCl2, final concentration 10 mM in blood) was gently dropped onto the surface of preheated PNPF powder at 37 °C (50 μL ACD whole blood was dropped into 100 mg PNPF powder). After that, the samples were incubated at 37 °C for 60, 120, 180 and 240 s, respectively. At the predetermined time points, 2.5 mL of distilled water was gently added to the test tube to dissolve the unbound RBCs, and then 200 μL of the supernatant was transferred to a 96-well plate and the absorbance at 540 nm was measured. Commercial gauze, gelatin sponge, chitosan powder and fibrin glue of the same size or mass were used as controls. Anticoagulated whole blood (50 μL) was introduced into distilled water (2.5 mL) as a negative control.

[0195] The blood coagulation index (BCI) was calculated using the following formula:

[0196] BCI (%) = [(A s -A0) / (A n -A0)]×100%,

[0197] Among them, A0, A n and A s Represent the absorbance of distilled water, negative control and sample respectively. The results are as follows Figure 8 shown.

[0198] Performance characterization: Figure 8 It can be seen that PNPF adhesive powder can completely coagulate blood within 60 s, and its coagulation ability is significantly better than that of commercial gauze, gelatin sponge, chitosan powder and fibrin glue.

[0199] Test Example 6

[0200] This test example evaluates the sealing ability of the prepared fibrin-based adhesive powder on biological tissues.

[0201] Test method: The burst pressure test was used to quantitatively analyze the sealing ability of PNPF. PNPF-0 and PNPF-2 were used for this test. The porcine small intestine tissue was fixed to the burst pressure test device (refer to Fig. 9 ), and a 2 mm incision was made on the surface of the small intestine with a scalpel. Before the test, PBS was sprayed on the surface of the small intestine to keep the surface moist. Then, 80 mg of PNPF-0 and PNPF-2 powder was sprinkled on the incision to form a sealing layer to seal the incision. Then, air was pumped into the device and the pressure was measured with a pressure gauge. The burst pressure refers to the maximum pressure before the wound seal is burst. The results are shown in Fig.10 .

[0202] Performance characterization: Fig.10 It can be seen that the bursting pressure of the prepared adhesive powder PNPF-0 is 98.93 mmHg, and the bursting pressure of PNPF-2 is 180.71 mmHg. This result shows that after adding the fibrin component, the sealing ability of the adhesive is significantly enhanced, which is significantly stronger than the normal human blood pressure of 120 mmHg, and is suitable for hemostasis of severe bleeding in the human body.

[0203] Test Example 7

[0204] This test example evaluates the hemostatic ability of the prepared fibrin-based adhesive powder.

[0205] Evaluation method: SD rats (120-150 g) were anesthetized by intraperitoneal injection of sodium pentobarbital solution (1%, w / v, 50 mg / kg). The rat tail was cut at 2 / 3 of its length, and the blood was allowed to flow out for 5 s to confirm the successful establishment of the bleeding model. Then, PNPF-0, PNPF-2, gelatin sponge, gauze and chitosan powder were pressed on the bleeding site. The hemostasis was observed every 15 s by separating the rat tail and the hemostatic material until complete hemostasis. Finally, the hemostasis time was recorded and the total amount of bleeding was calculated. A rat bleeding model was established, and the control group was set up without any hemostatic treatment. The results are shown in the figure. Fig.11 shown.

[0206] Performance characterization: Fig.11 It can be seen that the prepared fibrin-based adhesive powder is significantly superior to commercial gelatin sponge, gauze and chitosan powder in terms of hemostasis time and total bleeding volume. The hemostasis time can be as low as 133±22.99 s and 131±19.41 s, and the bleeding volume can be as low as 34.65±7.93 mg and 32.13±5. 88 mg, respectively, which has great potential for clinical application.

[0207] Test Example 8

[0208] This test example evaluates the wound healing ability of the prepared fibrin-based adhesive powder.

[0209] Evaluation method: Rats weighing 220-250 g were anesthetized by intraperitoneal injection of sodium pentobarbital solution (mass fraction 1%, dosage 50 mg / kg). The rats were fixed on a dissecting board in a prone position. The rats were randomly divided into 3 groups, 4 in each group, including PNPF-0, PNPF-2 and a control group. The hair on the back of the mouse was shaved, and a circular full-thickness skin incision with a diameter of 14 mm was made using surgical scissors. 0.5 mL of PBS was dripped onto the wound, and then PNPF-0 and PNPF-2 were covered on the wound, and gentle pressure was applied to ensure that the material was in full contact with the wound. For wound healing monitoring, the wound healing status was recorded and compared by taking pictures on days 0, 7, and 14. The results are as follows Fig.12 shown.

[0210] Performance characterization: Fig.12 The results show that the prepared fibrin-based adhesive powder has significantly better healing performance than the control group and the fibrin-free PNP group, and has great clinical application potential in promoting wound healing.

[0211] The above is only an embodiment of the present application and is not intended to limit the present application. For those skilled in the art, the present application may have various changes and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application should be included in the scope of the claims of the present application.

Claims

1. A bioadhesive, characterized in that: The bioadhesive comprises a double network system with uniform texture formed by a poly(acrylic acid-succinimide)-polyethyleneimine network and a fibrin network; The mass ratio of the fibrin network to the poly(acrylic acid-succinimide)-polyethyleneimine network is (0.1-10):(90-99.9); The poly(acrylic acid-succinimide)-polyethyleneimine network comprises a network system formed by cross-linking poly(acrylic acid-succinimide) and polyethyleneimine.

2. The bioadhesive according to claim 1, characterized in that The mass ratio of the poly(acrylic acid-succinimide) to polyethyleneimine is (0.5-5):(0.5-5), preferably (1-2):(2-1), and more preferably 1:

1.

3. The bioadhesive according to claim 1 or 2, characterized in that The poly(acrylic acid-succinimide) has a structure as shown in formula (I): (I), In formula (I), n is 100 to 4000, and m is 1 to 800; And / or, the molecular weight of the polyethyleneimine is 10,000-150,000.

4. The bioadhesive according to claim 1, characterized in that The fibrin network is obtained by reacting fibrinogen and thrombin in a mass ratio of (0.5-5):(0.5-5).

5. The bioadhesive according to claim 1, characterized in that The adhesive is in powder form with a particle size of 10-1000 μm.

6. The method for preparing the bioadhesive according to any one of claims 1 to 5, characterized in that: include: Step 1, respectively preparing a poly(acrylic acid-succinimide) solution, a polyethyleneimine solution, a fibrinogen solution and a thrombin solution; Step 2: Mixing the poly(acrylic acid-succinimide) solution and the thrombin solution to obtain a stock solution 1, and mixing the polyethyleneimine solution and the fibrinogen solution to obtain a stock solution 2; mixing the stock solution 1 and the stock solution 2 to form a hydrogel; Step 3: freeze-drying the hydrogel to prepare a powdered bioadhesive.

7. The method according to claim 6, characterized in that In the step 1, the prepared mass concentration of the poly(acrylic acid-succinimide) solution is 5% to 50%, the prepared mass concentration of the polyethyleneimine solution is 5% to 50%, the prepared mass concentration of the fibrinogen solution is 1% to 20%, and the prepared mass concentration of the thrombin solution is 1% to 20%; And / or, in step 2, the stock solution 1 and the stock solution 2 are stirred and mixed at room temperature for 60 to 240 seconds, then allowed to stand at 4°C for 3 to 10 minutes, and then transferred to a -40°C refrigerator for freezing for 6 to 24 hours; And / or, the freeze-drying conditions in step three are: freeze-drying at -40°C for 3 to 5 days.

8. The method according to claim 6, characterized in that The poly(acrylic acid-succinimide) is prepared by polymerization of acrylic acid and N-acryloyloxysuccinimide, and the reaction molar ratio is (100-4000): (1-800).

9. The method according to claim 8, characterized in that The polymerization reaction conditions are: reacting at 65°C to 75°C for 15 to 30 hours in a closed environment without oxygen; And / or, an initiator and a chain transfer agent are also added to the polymerization reaction; And / or, after the polymerization reaction is completed, dialysis and freeze-drying are performed.

10. Use of the bioadhesive according to any one of claims 1 to 5, or the bioadhesive prepared according to any one of claims 6 to 9, in the preparation of a wound-adjuvant treatment product; Preferably, the trauma auxiliary treatment products include protective products for hemostasis and wounds, tissue sealing products, drug delivery products and / or biological scaffolds; Preferably, the bioadhesive is suitable for moist wounds and / or dynamic wounds.